Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nis Register Study Comparing Seroquel and Seroquel Prolong

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00965536
First received: August 24, 2009
Last updated: February 15, 2011
Last verified: February 2011

August 24, 2009
February 15, 2011
August 2009
December 2010   (final data collection date for primary outcome measure)
  • Hospitalisation time [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Treatment practice [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Hospitalisation time [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]
  • Treatment practice [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00965536 on ClinicalTrials.gov Archive Site
  • Primary diagnosis [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Medication at the end of hospitalisation [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • GAF rating points [ Time Frame: 2008-2010 ] [ Designated as safety issue: No ]
  • Primary diagnosis [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]
  • Medication at the end of hospitalisation [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]
  • GAF rating points [ Time Frame: 2008-2009 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Nis Register Study Comparing Seroquel and Seroquel Prolong
A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.

The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The primary objectives of the study are:1.To collect information on the used Quetiapine Immediate Release or Quetiapine Extended Release medication 2.To collect information on duration and number of hospitalisation days 3.Change of GAF points

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

South Karelia Central Hospital in-patients

Comparing Hospitalisation Time With Seroquel and Seroquel Prolong
Not Provided
  • 1
    Seroquel
  • 2
    Seroquel Prolong
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Medication: Seroquel or Seroquel Prolong
  • Diagnosis: F20-F29 or F30-F31 (ICD-10)
  • In-patient

Exclusion Criteria:

  • None
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00965536
NIS-NFI-SER-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Director: Yrjö Ovaskainen Medical Affairs Manager, MD, psychiatrist
Principal Investigator: Kari Hänninen MD, psychiatrist
AstraZeneca
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP